Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen
详细信息 查看全文
- 作者：Denis Soulières ; Jose Luis Aguilar ; Eric Chen ; Krzysztof Misiukiewicz…
- 关键词：Carcinoma ; squamous cell ; Cetuximab ; Head and neck cancer ; Safety
- 刊名：BMC Cancer
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：16
- 期：1
- 全文大小：618 KB
- 参考文献：1.Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21 Suppl 7:vii252–61.PubMed
2.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancer. Version 2.2014. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf . Accessed 24 Nov 2014.
3.Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.PubMed CrossRef
4.Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646–54.PubMed CrossRef
5.Erbitux Prescribing Information. Revised August 2013. Branchburg, NJ: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company. http://packageinserts.bms.com/pi/pi_erbitux.pdf . Accessed 11 Nov 2014.
6.Erbitux Summary of Product Characteristics. Revised August 2014. Darmstadt, Germany: Merck KGaA. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000558/WC500029119.pdf . Accessed 26 Nov 2014.
7.A Study in Head and Neck Cancer. ClinicalTrials.gov study record. http://clinicaltrials.gov/show/NCT01081041 . Accessed 27 Nov 2014.
8.Platinol [product information]. Bristol-Myers Squibb Company 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s080lbl.pdf . Accessed 11 Nov 2014.
9.Carboplatin FDA Professional Drug Information. http://www.drugs.com/pro/carboplatin.html . Accessed 14 Nov 2016.
10.Adrucil (Fluorouracil) Injection. TEVA Parenteral Medicines, Inc. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0794add-67a7-4308-93e9-f889472716cc . Accessed 11 Nov 2014.
11.Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2866–72.PubMed CrossRef - 作者单位：Denis Soulières (1)
Jose Luis Aguilar (2)
Eric Chen (3)
Krzysztof Misiukiewicz (4)
Scott Ernst (5)
Hyun Jung Lee (6)
Katherine Bryant (6)
Shuang He (6)
Coleman K. Obasaju (6)
Shao-Chun Chang (6)
Steve Chin (6)
Douglas Adkins (7)
1. Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada
2. Instituto Nacional de Cancerologia, Mexico City, Mexico
3. Princess Margaret Hospital, Toronto, Ontario, Canada
4. Mount Sinai School of Medicine Tisch Cancer Institute, New York, NY, USA
5. London Regional Cancer Center, London, Ontario, Canada
6. Eli Lilly and Company, Indianapolis, IN, USA
7. Washington University School of Medicine, 660 S. Euclid, Box 8056, St. Louis, MO, 63110, USA - 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
- 出版者：BioMed Central
- ISSN：1471-2407
文摘
Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Cetuximab manufactured by ImClone (US commercial cetuximab) potentially results in higher systemic exposures than cetuximab manufactured by Boehringer Ingelheim (BI-manufactured cetuximab). This prospective, randomized, double-blind study compared the safety profiles of the two cetuximab formulations.